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ABSTRACT  
The insulin-like growth factors (IGF-I and IGF-II) stimulate cell growth, survival and 
differentiation, and have insulin-like activity. A family of six IGF-binding proteins 
(IGFBP-1 through -6) bind to IGFs with high affinity and modulate their activity in the 
circulation and locally at cell-surface receptors. IGFBPs can potentiate or inhibit IGF-
activity. Proteolysis is recognised as the predominant mechanism for IGF release from 
IGFBPs. IGFBPs have also IGF-independent effects, through the interaction with cell 
surface structures and extracellular molecules. IGFBP-1 and IGFBP-2 have a C-
terminal Arg-Gly-Asp (RGD) sequence, and IGFBP-1 has been shown to increase 
migration independently of IGF-I by binding to extracellular α5β1-integrins. An 
IGFBP-1- protease activity has previously been isolated from the urine of a patient with 
multiple myeloma and an inflammatory skin disease. Although it was not isolated in its 
active form, the protease-activity was identified as azurocidin. The aim of this thesis 
was to further characterize this protease-activity and to study the biological effects of 
the proteolytic IGFBP fragments on migration and on IGF-stimulated proliferation in 
human dermal fibroblasts. 
 
Intact IGFBP-1 and IGFBP-1 fragments, obtained by incubating with the patient-
derived protease-activity, were characterized in four RIAs and with SDS–PAGE. 
Immunoreactivity and size of fragments were compared to in vitro produced fragments. 
Serum from the patient inhibited IGFBP-1 protease activity; however, immunoreactive 
IGFBP-1 in patient serum was present at molecular masses consistent with IGFBP-1 
fragments, in addition to intact IGFBP-1. We also studied a neutrophil-derived 
preparation of azurocidin and found that it cleaved IGFBP-1, IGFBP-2 and IGFBP-4. 
IGFBP-1 bound to IGF-I was also degraded whereas IGF-II was shown to have an 
inhibitory effect on proteolysis of IGFBP-1. The proteolytically active preparation of 
neutrophil-derived azurocidin was found to be glycosylated and determined to be 31 
kDa by SDS-PAGE. The same cleavage pattern of IGFBP-1 was obtained by both 
azurocidin-preparations derived from either urine or neutrophils. IGFBP-1, IGFBP-2 
and their proteolytic fragments stimulated migration of fibroblasts and the stimulatory 
effect was abolished by pre-treating cells with an α5β1 integrin antibody. High glucose 
impaired migration. However, the addition of IGFBP-1, IGFBP-2 or fragments 
increased migration to normal levels again. IGFBP-2 inhibited IGF-II induced 
proliferation, while IGFBP-2 fragments had reduced inhibitory effect. Intact 
phosphorylated IGFBP-1 showed either potentiating or inhibitory effects on IGF-I 
induced proliferation depending on the confluence of cells, and proteolysis of IGFBP-1 
did not change these effects. 
 
In conclusion, a novel IGFBP-protease which is associated to inflammation regulates 
IGF-activity in tissue through cleavage of IGFBPs, resulting in proteolytic IGFBP-
fragments with biological effects important for tissue repair. 
 
Keywords: Insulin-like growth factor, IGF-binding protein-1, IGF-binding protein-2 
IGF-binding protein-4, IGFBP protease, azurocidin/heparin binding protein/CAP37, 
inflammation, migration, proliferation, high glucose 
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1 INTRODUCTION 
 
1.1 THE INSULIN-LIKE GROWTH FACTORS  
The insulin-like growth factors (IGF-I and IGF-II) are small homologues peptides 
of approximately 7 kDa, which are structurally similar to insulin. They are expressed in 
most organs and promote cell growth, survival and differentiation, and have insulin-like 
activity (Enberg et al., 1984; Jones and Clemmons, 1995). IGFs function in an 
endocrine fashion as a hormone and locally as autocrine/paracrine factors. Growth 
factors are essential for normal growth and development.  
 
1.1.1 IGF-receptors 
The biological actions of IGFs are primarily mediated through the type 1 IGF 
receptor (IGF-1R) located at the cell surface (Furlanetto et al., 1987; Jones and 
Clemmons, 1995; Le Roith et al., 2001a). This receptor belongs to the tyrosine kinase 
receptor family and ligand binding induces IGF-1R auto-phosphorylation. The 
activated IGF-1R can then activate multiple signal transduction cascades, including the 
mitogen-activated protein (MAP) kinase pathway and the phosphatidylinositol-3-kinase 
(PI3-kinase)-Akt pathway (Duan and Xu, 2005). The IGF-1R receptor has a high 
degree of homology with the insulin receptor, which IGFs also can bind to, although 
with lower affinity compared with the IGF-1R. IGFs can exert insulin-like activity in 
tissues expressing high levels of IGF-1R (skeletal muscle, pancreatic β-cells (Silha, 
2005). As a result of the close homology between IGF-1R and insulin receptors there 
are also hybrid IGF/insulin receptors, which bind to IGFs and insulin with similar 
affinities as the IGF-1R. The IGF-1R has 2- to 15-fold lower affinity for IGF-II 
compared with IGF-I (Jones and Clemmons, 1995; Le Roith et al., 2001a).   
The IGF-II receptors have high affinity for IGF-II, however, there is no known 
IGF signalling mediated through this receptor. Binding of IGF-II to this receptor causes 
internalization and degradation of IGF-II and thereby reduces the levels of IGF-II, 
which is it’s primarily responsibility during fetal development. The IGF-II receptors are 
identical to the cation-independent mannose 6-phosphate receptors which function in 
the trafficking of lysosomal enzymes (Le Roith et al., 2001a). 
.  
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1.1.2 Regulation of IGFs 
Growth hormone (GH) stimulates the production of hepatic IGF-I, which is the 
major source of circulating IGFs (Le Roith et al., 2001a). GH also induces IGF-I 
expression in many tissues e.g. liver, muscle, pancreas, intestine, kidney, adipose tissue 
and brain (Roberts et al., 1987). IGF-I was previously known as somatomedin and 
according to the original “somatomedin hypothesis”, the effects of GH on postnatal 
growth were mediated by IGF-I, which was secreted into the circulation from the liver. 
However, it was later discovered that IGF-I was produced locally in most tissues. The 
hypothesis was therefore revised to include an autocrine/paracrine function of IGF-I, 
which also was believed to be regulated by GH. Later studies have shown that there are 
other factors, besides GH, that can stimulate expression of IGF-I (Le Roith et al., 
2001b). For example estrogen induces mRNA expression of IGF-I in the uterus, 
follicle-stimulating hormone (FSH) stimulates expression in the ovary and parathyroid 
hormone (PTH) and estrogen increase expression in bone (Hatey et al., 1992; Murphy 
et al., 1987). Nutrition is one of the major regulators of IGF-I in the circulation. IGF-I 
has anabolic effect on protein metabolism and is reduced by food deprivation and in 
catabolic stress (J.P Thissen, 2005).  
The liver-specific igf-1 gene deleted mouse (LID mouse) model has revealed that 
liver-derived IGF-I is not essential for postnatal growth (Sjogren et al., 1999; Yakar et 
al., 1999). However, subcutaneous IGF-I therapy resulted in significant growth 
response in patients with GH receptor dysfunction or IGF-I gene deletion, implicating 
the importance of endocrine IGF-I for human growth (Azcona et al., 1999; Camacho-
Hubner et al., 1999; Ranke et al., 1999). Liver-derived IGF-I has also been shown to be 
involved in the regulation of blood pressure in LID mice (Tivesten et al., 2002). 
Inflammatory cytokines can act systemically to impair IGF-I synthesis but also to affect 
growth locally. IL-1b and TNF-alpha inhibited longitudinal growth in fetal rat 
metatarsal bones which was partly reversed by IGF-1 (Martensson et al., 2004; 
Schmeling et al., 2003). 
 
1.2 IGF-BINDING PROTEINS 
The activity of IGF-I and IGF-II is regulated by a family of six IGF binding-
proteins (IGFBPs), which bind to IGFs with high affinity. These binding proteins serve 
as carriers of IGFs, prolong IGF half-life in the circulation and modulate IGF activity at 
cell-surface receptors (Firth and Baxter, 2002a; Jones and Clemmons, 1995). IGFs in 
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the circulation are mainly transported in a 150 kDa ternary complex with IGFBP-3 and 
the acid-labile subunit (ALS).  The ternary complex is too large to cross the endothelial 
cell layer and prolongs the very short half-lives of IGFs in the circulation by 
approximately 12-15 h. The complex is considered to be the storage pool of IGFs and 
IGFs are released from this 150 kDa-complex principally by limited proteolysis of 
IGFBP-3 (Jones and Clemmons, 1995; Rechler and Clemmons, 1998). All members of 
the ternary complex are induced by GH and it is assumed that the complex formation 
occurs in the liver since IGF-I and ALS are produced by hepatocytes, whereas IGFBP-
3 is derived from Kuppfer cells (Arany et al., 1994; Chin et al., 1994). IGFBP-5 has 
also been shown to be part of a ternary complex, although too much lesser extent (Firth 
and Baxter, 2002a). 
IGFs also exist in smaller binary complexes (40-50 kDa) together with IGFBPs. 
The binary complexes have the ability to cross the vascular wall and that makes them 
important IGF transporters to target tissues, where IGFs elicit hormonal growth-
stimulating effects through the IGF-1R (Jones and Clemmons, 1995). Free IGFs 
disappears from the circulation within minutes (Hodgkinson et al., 1989) (Figure 1). 
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IGFBPs are expressed in many peripheral tissues and each IGFBP has specific 
tissue production which results in tissue-specific actions of IGFs (Lee et al., 1997). 
IGFBP-4 and IGFBP-6 have been consistently found to inhibit IGF activity, while 
IGFBP-1, 2, -3 and -5 can inhibit or potentiate IGF actions in vitro (Duan and Xu, 
2005; Mohan and Baylink, 2002). IGFBP-1 has earlier been shown to potentiate IGF-
stimulated proliferation in cell cultures of human, mouse and chicken embryo 
fibroblasts (Elgin et al., 1987). Non-phosphorylated IGFBP-1 has been reported to be 
associated with potentiation of IGF-I activity, while phosphorylated IGFBP-1 has been 
reported to inhibit IGF action (Jyung et al., 1994). Pre-incubations of human skin 
fibroblasts with IGFBP-3 potentiated IGF-I stimulation, in contrast to co-incubation of 
IGF-I and IGFBP-3, which caused inhibition of proliferation (De Mellow and Baxter, 
1988).  IGFBP-5 bound to extracellular matrix (ECM) was found to potentiate IGF-I 
induced cell proliferation (Jones et al., 1993b).  
 
1.2.1 IGFBP-1 
Povoa et al. isolated and characterized the first IGF-binding protein from mid-term 
amniotic fluid and developed a radioimmunoassay in our laboratory in 1984, which 
measured both phosphorylated and non-phosphorylated IGFBP-1(Povoa et al., 1984a; 
Povoa et al., 1984b).   
IGFBP-1 has a rapid turnover and a marked circadian rhythm with several-fold 
higher levels during night compared to in the afternoon (Brismar et al., 1988). The 
serum levels of IGFBP-1 are age dependent with the highest levels at birth and lowest 
during adolescence (Hall K., 1988). Endocrine IGFBP-1 is mainly produced in liver 
and is secreted in a highly phosphorylated form that has high IGF-I affinity (Lewitt, 
1994). Unlike other IGFBPs, IGFBP-1 is acutely regulated in response to insulin and is 
likely to have an important endocrine function in nutrition by inhibiting the insulin-like 
activity of IGFs (Brismar et al., 1994; Brismar et al., 1988; Lee et al., 1997; Lewitt, 
1994; Tivesten et al., 2002). IGF-I lower blood glucose levels directly by stimulating 
glucose uptake in cells and indirectly by increasing insulin sensitivity in tissues 
(Wheatcroft and Kearney, 2009). IGFBP-1 is increased during short-term fasting due to 
nutritional deprivation and in response to insulin-induced hypoglycaemia (Bang et al., 
1994b; Lewitt, 1994). Circulating IGFBP-1 is predominantly regulated by insulin, 
which inhibits the expression of IGFBP-1 at the transcriptional level in hepatocytes 
(Brismar et al., 1994; Durham et al., 1999). Besides insulin and nutrition, IGFBP-1 is 
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also regulated by cytokines, GH, IGFs, hypoxia and stress hormones (Brismar et al., 
1995; Hilding et al., 1993; Silha, 2005) (Table 1). 
Tissue-specific gene expression of IGFBP-1 has also been detected in kidney, 
decidualized stromal cells of the uterine endometrium and in luteinizing ovarian 
granulosa cells (Lee et al., 1997). In conditions with inflammation, IGFBP-1 can be 
expressed for example in atherosclerotic plaque (Wang et al., 2011). A number of 
studies indicate a role of IGFBP-1 as a regulator of IGF bioavailability in embryonic 
growth. IGFBP-1 increases in maternal circulation, is the predominant IGFBP in 
amniotic fluid and a major IGF-binding protein in fetal plasma (Drop et al., 1984; Han 
et al., 1996; Kajimura et al., 2005). IGFBP-1 modulates the free fraction of IGFs in 
serum and can thus be used as a surrogate marker of free IGF-I(Frystyk et al., 1994).  
 
Table 1. Regulators of IGFBP-1 and IGFBP-2 
      
  IGFBP-1 IGFBP-2 
Fasting ↑ ↑ 
Amino acids ↓ 
 Nutrition 
 
↓ 
Insulin ↓ ↓ 
Cortisol ↑ ↓ 
Catecholamines ↑ 
 Glucagon ↑ 
 GH ↓ ↓ 
IGFs ↓ 
 Cytokines ↑ 
 Leptin ↓ ↑ 
Hypoxia ↑   
 
 
1.2.2 IGFBP-2 
IGFBP-2 is the second most abundant binding protein in the circulation and is 
predominantly expressed in adipocytes, liver, reproductive system and central nervous 
system (Shimasaki and Ling, 1991; Wheatcroft and Kearney, 2009). IGFBP-2 is the 
dominating IGFBP in adipose tissue, lymph, bronchoalveolar lavage, prostate and 
seminal fluid (Chadelat 1998, Rosenfeld 1990). In general, the function of IGFBP-2 is 
to inhibit IGF actions, in particular IGF-II, since it has a higher affinity for IGF-II than 
IGF-I (Firth and Baxter, 2002a). Little is known about post-translational modifications 
of IGFBP-2. Circulating IGFBP-2 is inhibited by insulin, however, less rapidly than 
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IGFBP-1.  IGFBP-2 is also inhibited by GH and increased after extended fasting 
(Table 1). IGFBP-2 levels correlates inversely with body mass and insulin 
concentrations (Silha, 2005; Wheatcroft and Kearney, 2009). IGFBP-2 has been 
suggested as a marker for the metabolic syndrome, since these patients have lower 
IGFBP-2 concentrations (Heald et al., 2006).  
 
1.2.3 IGFBP-4 
IGFBP-4 is widely expressed in different tissues, with the highest expression in 
liver. IGFBP-4 can be N-glycosylated and does not bind to cell surface (Rechler and 
Clemmons, 1998; Shimasaki et al., 1990). The regulation of IGFBP-4 is cell type 
specific (Silha, 2005). IGFBP-4 is a potent inhibitor of IGF action in a variety of cell 
types, including bone and vascular smooth muscle cells. The inhibitory effect of 
IGFBP-4 on IGF is regulated by proteolysis of IGFBP-4, which results in release of 
free IGFs (Firth and Baxter, 2002a). 
 
1.2.4 Post-translational modifications of IGFBPs 
The six IGFBPs have a mass of 24-45 kDa and are organized into three domains of 
approximately equal size. The N- and C-terminal domains of IGFBPs are conserved 
and cysteine rich (Mohan and Baylink, 2002). The non-conserved linker-domain (L-
domain) is susceptible to post-translational modifications such as glycosylation, 
phosphorylation and proteolysis (Firth and Baxter, 2002a).  
The high affinity interactions between IGFs and IGFBPs prevent binding of IGF to 
IGF-1R. Since the affinity of IGFs for IGFBPs are higher than their affinity for the 
IGF-1R, IGFBPs must be modified by post-translational modifications in order to 
release IGFs. Three post-translational modifications have been shown to influence the 
IGF binding affinity of IGFBPs (Duan and Xu, 2005; Mohan and Baylink, 2002). See 
Table 2 for biochemical properties of IGFBPs.  
 
1.2.4.1 Proteolysis of IGFBPs 
Proteolysis of IGFBPs reduces their inhibitory effect on IGF actions and occurs 
predominantly in the non-conserved mid-region of IGFBPs (Bunn and Fowlkes, 2003; 
Firth and Baxter, 2002a). Proteases which can cleave IGFBPs into fragments with 
reduced affinity for IGFs have been identified in a variety of biological fluids.  All six  
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Table 2. Biochemical properties of IGFBPs 
  IGFBP-1 IGFBP-2 IGFBP-3 IGFBP-4 IGFBP-5 IGFBP-6 
ALS binding 
  
+ 
 
+ 
 Glycosylation 
  
+ + + + 
Heparin binding sequence 
 
+ + 
 
+ + 
Cell surface/ECM binding 
 
+ + 
 
+ 
 RGD sequence + + 
    Nuclear localization sequence 
  
+ 
 
+ 
 Ser phosphorylation sites + 
 
+ 
 
+ 
 Size (kDa) 25 31 43-45 24 29 28-30 
 
IGFBPs can be cleaved by various IGFBP proteases and  proteolytic cleavage has been 
recognised as the predominant mechanism for IGF release from IGFBPs (Bunn and 
Fowlkes, 2003). Proteolysis of IGFBP-3 and IGFBP-5 sometimes results in fragments 
with retained affinity for IGFs. IGFBP-3 and IGFBP-5 fragments have also been shown 
to potentiate IGF activity. In contrast, the proteolytic fragments of IGFBP-2 and 
IGFBP-4 have significantly reduced affinities for IGFs (Jones and Clemmons, 1995). 
The N-domain of IGFBPs contains the major IGF binding site, but C-domains also 
contribute to the ligand-binding capacity (Clemmons, 2001). The relative IGF-binding 
affinities of isolated N- and C-domains differ among IGFBPs. The N- and C-terminal 
domains of IGFBP-2 cooperate in IGF binding and are both required to form a high 
affinity complex (Carrick et al., 2001) . The amino-terminal domain is required for 
rapid binding of IGFBP-2 to IGF, while the carboxyl-terminal has higher affinity and is 
required to maintain IGFBP-2 and IGF in a complex form. Co-incubation of the N- and 
C-domains of IGFBP-2 did not enhance IGF-binding (Carrick et al., 2001). In contrast, 
the N-domain of IGFBP-4, -5 and -6 has higher affinity for IGF compared to the C-
domain (Bach et al., 2005; Kalus et al., 1998; Standker et al., 2000).  
 
1.2.4.2 Phosphorylation of IGFBPs 
IGFBP-1, IGFBP-3 and IGFBP-5 can be serine phosphorylated (Coverley and 
Baxter, 1997). IGFBP-1 is secreted by liver in a highly phosphorylated form that has 
high IGF-I affinity (Lewitt, 1994). Serine residues 101, 119 and 169 on IGFBP-1 can 
be phosphorylated which leads to a 6-7 fold increase in affinity for IGF-I (Jones et al., 
1993a). The phosphorylated form of IGFBP-1 was first reported to be resistant to 
proteolysis, however, Wang et al. recently showed that the phosphorylated form of 
IGFBP-1 was efficiently cleaved by a protease activity purified from urine (Wang et 
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al., 2006b) Phosphorylation of IGFBP-3 protects against degradation in vitro and 
inhibits cell surface binding (Coverley et al., 2000). However, phosphorylation of 
IGFBP-3 does not appear to influence IGF binding affinity (Coverley and Baxter, 
1997). 
 
1.2.4.3 Binding of IGFBPs to extracellular matrix and cell surface 
IGFBP-3 and IGFBP-5 can bind to the cell surface or extracellular matrix which 
has been shown to reduce their affinities for IGF-I (Mohan and Baylink, 2002). Binding 
of IGFBP-3 to fibroblasts reduced its affinity for IGF-I compared to IGFBP-3 in 
solution (Conover and Powell, 1991), while binding of IGFBP-5 to ECM lowered its 
binding affinity for IGF-I (Jones et al., 1993b). IGFBP-5 can bind to 
glycosaminoglycan (GAG) present in the ECM, which can result in cell association of 
IGFBPs and potentiation of IGF activity (Bach et al., 2005; Mohan and Baylink, 2002). 
IGFBP-5 associated to ECM is not cleaved by proteases, has reduced affinity for IGFs 
and potentiates IGF action (Firth and Baxter, 2002a).  
Glycosylation of the non-conserved L-domain of IGFBPs affects stability, cell 
association, susceptibility to proteolysis and circulating half-life (Firth and Baxter, 
2002a; Marinaro et al., 2000a; Marinaro et al., 2000b).  
 
1.2.5 IGF-independent effects of IGFBPs 
IGFBPs also possess intrinsic IGF-independent effects on e.g. cell growth, 
differentiation and apoptosis. There have been reports of three groups of 
macromolecules which are capable of binding to IGFBPs, and possibly through which 
they could activate signalling pathways on their own (Ricort, 2004). 
 
1.2.5.1 Trans-membrane IGFBP receptors 
IGFBP-1 and IGFBP-2 contain a C-terminal Arg-Gly-Asp (RGD) sequence which 
can associate with cell-surface α5β1-integrin (fibronectin receptor) (Brewer et al., 1988; 
Jones et al., 1993c). Integrins are trans-membrane proteins which mediate interactions 
between the cytoskeleton and the extracellular matrix. The RGD sequence is also 
present in several extracellular matrix proteins such as fibronectin and vitronectin and 
is considered essential for cellular attachment of these proteins (Pierschbacher et al., 
1982). Several studies have shown that IGFBP-1 increase migration independently of 
IGF-I by binding to α5β1-integrins (Gleeson et al., 2001; Jones et al., 1993c; Perks et 
al., 1999).For example IGFBP-1 stimulates human trophoblast migration by signalling 
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through α5β1-integrin via MAP kinase pathway (Gleeson et al., 2001). There are only a 
few studies that have reported IGF-independent effects of IGFBP-2 through 
interactions of the C-terminal RGD sequence with α5β1-integrins (Wheatcroft and 
Kearney, 2009). Binding of IGFBP-2 to the cell surface has been shown in the rat brain 
olfactory bulb (Russo et al., 1995) and Wang et al. has reported that IGFBP-2 induces 
migration through interaction with integrin α5 and this was mediated through the RGD 
domain on IGFBP-2 (Wang et al., 2006a). IGFBP-5 has been shown to bind to an un-
identified 420 kDa membrane protein in osteoblastic cells, which is followed by 
internalization of IGFBP-5 (Andress, 1995).  
 
1.2.5.2 Extracellular matrix receptors 
The C-terminal domains of IGFBP-3 and IGFBP-5  have heparin-binding domains 
(HBD) which are involved in most of the IGF-independent interactions of these 
binding-proteins (Firth and Baxter, 2002a). IGFBP-2 can interact with 
glycosaminoglycans (GAGs), but only in the presence of IGFs (Arai et al., 1996). 
IGFBP-4 has no HBD and has not been reported to interact with molecules on the cell 
surface (Firth and Baxter, 2002a) 
 
1.2.5.3 Intracellular IGFBP receptors 
Structural analyses of IGFBPs have revealed nuclear localization signals (NLS) in 
the C-terminal domain of IGFBP-3 and IGFBP-5 (Radulescu, 1994). There are several 
reports on IGFBP-3 located in the nucleus of cells (Lee and Cohen, 2002). IGFBP-5 
has been shown to translocate to the nucleus in human breast cancer cells via the 
cytosolic IGFBP-5 “receptor” importin-β (Schedlich et al., 2000; Schedlich et al., 
1998). 
Several IGFBPs have been reported to have both anti- and pro-apoptotic effects 
(Ricort, 2004). IGFBP-3 inhibits cell growth independently of IGFs  and IGF-1R (Butt 
and Williams, 2001) and induces apoptosis in human prostate cancer cells (Hong et al., 
2002). IGFBP-1 induces apoptosis in human breast cancer cells by interacting with 
integrin receptors (Perks et al., 1999). 
IGFBP-fragments have also been reported to have IGF-independent effects. Sala et 
al. demonstrated that a C-terminal fragment isolated from amniotic fluid has IGF-
independent effect on cell migration (Sala et al., 2005).  
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1.2.6 IGFBP proteases 
IGFBP proteases have been identified in several body fluids and from conditioned 
media of various cell cultures (Conover, 1995; Rajaram et al., 1997). Protease 
inhibitors have been used to identify IGFBP proteases from several major classes of 
proteases; serine proteases, metalloproteinases, aspartic acid proteases and cysteine 
proteases. IGFBP proteases can be relatively specific or non-specific to a certain 
IGFBP. 
Increased proteolysis of IGFBP-3 in serum has been observed during several 
pathological and physiological situations of increased growth like pregnancy and 
catabolic states. The pregnancy-associated IGFBP-3-specific protease was one of the 
first identified IGFBP proteases. This protease is specific to the reproductive tissues 
and releases IGFs in the second trimester of human to increase fetal growth (Giudice et 
al., 1990; Hossenlopp et al., 1990; Rajaram et al., 1997). An IGFBP-3 specific protease 
has been detected in the circulation during sever illness (Davies et al., 1991) and 
patients with acute and chronic renal failure had an increase of IGFBP-3-specific 
protease and absence of intact IGFBP-3 in urine (Lee et al., 1994). Increased levels of 
IGFBP-3 proteolysis has also been detected in patients with Type 2 diabetes (Bang et 
al., 1994a) and Type 1 diabetes in children (Bereket et al., 1995).  It is believed that 
IGFBP-3 proteolysis occurs in catabolic conditions to increase bioactive IGFs. 
Matrix metalloproteinases (MMP) secreted from human dermal fibroblasts has 
been reported to degrade IGFBP-3 and IGFBP-5 (Fowlkes et al., 1994; Nam et al., 
1996).  The lysosomal proteinase cathepsin D cleaves IGFBP 1-5, IGF-I and IGF-II 
under acidic conditions (Claussen et al., 1997; Conover and De Leon, 1994). It has 
been suggested that cathepsins participate in the clearance of IGFBPs and/or  IGFBP-
IGF complexes (Bunn and Fowlkes, 2003). 
An IGFBP-4 specific protease was partially purified from human fibroblasts and 
identified as the pregnancy-associated plasma protein-A (PAPP-A). This protease was 
also found to be expressed by vascular smooth muscle cells, ovarian granulosa cells, 
osteoblasts and placental trophoblasts. Recent studies, however, indicate that IGFBP-2 
and IGFBP-5 also may be substrates for PAPP-A (Boldt and Conover, 2007).  
An IGFBP-5 protease was partially purified from human fibroblasts and identified 
as the serine protease complement protein 1s, which is part of the complement cascade 
(Busby et al., 2000).  
The neutrophil-granular serine proteases elastase and cathepsin G, known as 
extracellular matrix degrading enzymes, have been reported to cleave all six IGFBPs 
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(Gibson and Cohen, 1999). A protease activity specific for IGFBP-1 was purified from 
the urine of a patient with multiple myeloma and an inflammatory skin disease (Wang 
et al., 2006b). This protease activity was identified as azurocidin, based on the presence 
of azurocidin in partially purified material from urine and the inhibitory effect of an 
antibody to azurocidin.  
 
1.2.6.1  Regulation of IGFBP proteases 
Proteolysis of IGFBPs is regulated by a variety of systemic and local mediators 
(Bang, 1995; Braulke et al., 1995; Clemmons et al., 1995; Collett-Solberg and Cohen, 
1996; Conover, 1995; Fowlkes et al., 1995; Hughes et al., 1995; Rajah et al., 1995).  
Insulin has been shown to regulate the IGFBP-3-specific activity as untreated 
Type 2 diabetes and Type 1 diabetes patients have increased serum levels of IGFBP-3 
protease, which declines after insulin therapy (Rajaram et al., 1997). 
Proteolysis of IGFBP-4 and IGFBP-2 by PAPP-A in cell-free assays have been 
shown to be IGF-dependent with IGF-II generally being more effective than IGF-I at 
stimulating proteolysis. Cleavage of IGFBP-5 by PAPP-A, however, is IGF-
independent (Boldt and Conover, 2007). In contrast to PAPP-A, the proteolytic activity 
of a metalloproteinase secreted from human fibroblasts was inhibited by IGF-II (Bunn 
and Fowlkes, 2003). The proteolytic activity of a human fibroblast derived protease 
was decreased when IGFBP-5 was bound to ECM. Therefore it has been suggested that 
that ligand-induced conformational changes of IGFBPs can determine the ability of 
IGFBPs to be degraded by IGFBP proteases (Bunn and Fowlkes, 2003). 
 
1.3 THE IGF-SYSTEM IN HEALTH AND DISEASE   
The IGF system is important in normal physiology and alterations are observed in 
pathological conditions. The expression of IGFs is age-dependent and normal levels 
range between 100-300 µg/L (Hilding et al., 1995). IGF-II predominates in the prenatal 
stage and is four times higher than IGF-I in human adults. IGF-I concentrations 
increase slowly in childhood and reaches the highest levels during puberty, and is then 
continuously decreased with age (Hilding et al., 1995; Juul, 2003; Lewitt, 2005).  
Studies using the IGF-I and IGF-II knockout mice have shown that IGF-I and IGF-
II are essential for fetal and postnatal growth, and survival. IGF-I knockout mice are 
born small and exhibit poor postnatal growth, if they survive at all (Liu et al., 1998; Liu 
et al., 1993). These animals are severely growth retarded and infertile. The IGF-II 
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knock-out mice had lower body weight at birth compared with the controls, however, 
they continued to grow postnatally at a rate similar to the wild-type mice. Although GH 
is not essential for prenatal growth, postnatal GH deficiency results in growth 
retardation (Gluckman et al., 1981). However, IGF-I infusion restores growth in GH-
deficient mice (Guler et al., 1988).  
Low levels of IGF-I are associated with Type 1 diabetes mellitus (T1DM) and 
IGF-I treatment improves glucose and protein metabolism and attenuates diabetic 
cardiomyopathy (Brismar et al., 1995; Camacho-Hubner et al., 1999; Carroll et al., 
2000; Norby et al., 2002). The glycaemic control in type 2 diabetic patients was 
improved by IGF-I treatment (Moses et al., 1996) and skeletal muscle IGF-1R knock-
outs resulted in insulin resistance and later development of type 2 diabetes mellitus 
(T2DM) (Fernandez et al., 2001; Lewitt et al., 2008; Petersson et al., 2009). Low 
IGFBP-1 levels are associated with insulin resistance and with cardiovascular disease 
risk, while decreased concentrations of IGFBP-2 are associated with obesity and has 
been suggested to be a marker for the metabolic syndrome (Heald et al., 2006; 
Wheatcroft and Kearney, 2009).  
Epidemiological studies have shown that increased levels of IGF-I is a risk factor 
for the development of breast, prostate, colon and lung cancer. Besides, abnormally 
high levels of IGFs and/or IGF-1R have been detected in a number of tumour cells 
(LeRoith and Roberts, 2003). IGF-II is often up-regulated in cancer and has been 
proposed to be an autocrine regulator in tumor cells (Sciacca et al., 1999). In early 
breast cancer circulating free IGFs was shown to be elevated, while total IGF-II was 
decreased (Espelund et al., 2008).  
Brain injury induces expression of IGF-I and IGF-1R and exogenous IGF-I 
treatment improved damages (Guan et al., 2003). IGF-I treatment have also been shown 
to have positive effects on Alzheimer disease and ALS (Carro et al., 2002; Kaspar et 
al., 2003). 
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1.4 AZUROCIDIN – AN INFLAMMATORY MEDIATOR 
In 1984 Shafer et al purified an antimicrobial protein of 37 kDa from the granules 
of human neutrophils and named it cationic antimicrobial protein of 37 kDa (CAP37) 
(Shafer et al., 1984b)(Shafer, Martin et al. 1984)(Shafer, Martin et al. 1984)(Shafer, 
Martin et al. 1984)(Shafer, Martin et al. 1984) (Shafer, Martin et al. 1984). Wilde et al. 
isolated azurocidin from the azurophilic granuels of human neutrophils (Wilde et al., 
1990b) and Flodgaard et al. isolated heparin-binding protein (HBP) by heparin affinity 
chromatography from human neutrophils (Flodgaard et al., 1991b). CAP37, HBP and 
azurocidin are three different names for the same protein and we will refer to this 
protein as azurocidin.  
Azurocidin belongs to the serprocidin family of serine protease homologues 
(Flodgaard et al., 1991a) and is closely structurally related to three other neutrophil 
granule proteins; elastase, proteinase 3 and cathepsin G (Almeida et al., 1991b; Morgan 
et al., 1991a). Azurocidin has been considered proteolytically inactive due to the 
replacement of serine and histidine in the serine protease catalytic triad (Campanelli et 
al., 1990a; Pereira et al., 1990a; Wilde et al., 1990a). However, the inactive “catalytic 
site” of human azurocidin can still bind to the bovine pancreatic trypsin inhibitor 
(BPTI) or aprotinin (Petersen et al., 1993) and BPTI-affinity chromatography has been 
shown to be a very efficient method to purify azurocidin (Watorek et al., 1996). 
 
1.4.1 Structure and biosynthesis of azurocidin 
Azurocidin is constitutively expressed during the promyelocyte stage of neutrophil 
differentiation and the proproteins are stored in the neutrophil granules (Gullberg et al., 
1999).   
Azurocidin is synthesized as a 251 amino-acid precursor, which is processed by 
removal of 26 amino acids from the N-terminus and three residues from the C-terminal 
(Almeida et al., 1991a; Morgan et al., 1991b). The mature protein is a single 
polypeptide, which consists of 222 amino-acid residues and has a calculated mass of 24 
kDa (Pohl et al., 1990). Three N-linked glycosylation sites have been identified located 
at asparagine residues 100, 114 and 145 and the differences in the reported molecular 
masses (29–37 kDa) are probably due to different degrees of glycosylation (Watorek, 
2003). Recombinant non-glycosylated azurocidin has been shown to have lower 
biological activity compared to glycosylated azurocidin, which suggests that 
glycosylation of azurocidin affects its biological activity (Iversen et al., 1999). 
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1.4.2 Biological activities 
Azurocidin is a multifunctional protein with important functions in host defence 
and inflammation (Pereira, 1995).  
 
1.4.2.1 Antimicrobial activity 
Azurocidin was first recognized for its bactericidal activity preferentially towards 
gram-negative bacteria, particularly Salmonella typhimurium and Escherichia coli 
(Shafer et al., 1984b; Shafer et al., 1986). The antimicrobial activity of azurocidin 
depends on ionic strength and pH and demonstrates activity in the concentration range 
of 10-5-10-6 (Gabay et al., 1989; Shafer et al., 1986; Spitznagel, 1990). Pereira et al. have 
produced synthetic peptides to determine which part of azurocidin is important for the 
antibacterial activity and found that residues 20-44 of azurocidin has the highest 
bacterial activity, however, 10-fold lower than intact azurocidin (Pereira et al., 1993). 
Maximum activity of the peptide was determined at pH 5.0 – 5.5, and the activity was 
decreased at pH 7.0. This peptide also binds to lipopolysaccharide (LPS) and lipid A 
component of LPS, and has been shown to inactivate LPS-induced responses (Brackett 
et al., 1997; Pereira et al., 1993). LPS, also known as endotoxin, is the major 
component of the outer membrane of gram-negative bacteria.  
Azurocidin might be a valuable tool to determine sepsis at an early stage, since 
azurocidin increases in sepsis and the levels correlate with the development of 
hypotension and circulatory failure (Linder et al., 2009). 
 
1.4.2.2 Interaction with endothelium 
 Acute inflammation is characterized by infiltration and accumulation of 
polymorphonuclear leukocytes (PMN) or neutrophils into the inflamed tissue 
(Soehnlein et al., 2009). The first wave of neutrophils dominates the inflamed tissue for 
the first three hours, which is followed by a second wave of emigrating monocytes 
(Rebuck and Crowley, 1955). In sub-acute and chronic inflammatory reactions 
monocytes and lymphocytes are the dominating extravasated cells. Azurocidin is stored 
in both azurophilic/primary granules and secretory vesicles of neutrophils and can be 
almost completely released into the extracellular environment following neutrophil 
activation (Tapper et al., 2002). The secretory vesicles are rapidly mobilized upon 
interaction of neutrophils with the vessel wall and azurocidin is the only granule protein 
released from these vesicles (Soehnlein et al., 2008; Tapper et al., 2002).  Azurocidin is 
a potent chemoattractant for monocytes (Pereira et al., 1990b) and the rapid discharge 
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of azurocidin is linked to the early recruitment of inflammatory monocytes (Soehnlein 
et al., 2008). Azurocidin is also stored together with elastase, cathepsin G and 
proteinase-3 in the azurophilic/primary granules which are released slowly and with 
low tendency into the extravascular space (Tapper et al., 2002).   
Adhesion of neutrophils to the endothelium causes release of azurocidin, which is 
mediated by leukocytic β2 integrin signalling (Gautam et al., 2001). The molecule of 
azurocidin has a strong dipole moment caused by basic amino acids concentrated on 
one side of the molecule (Iversen et al., 1997). The basic patch of secreted azurocidin 
binds to negatively charged proteoglycans on the endothelial cell membrane (Olofsson 
et al., 1999), which induces Ca2+-dependent cytoskeletal rearrangement, cell contraction 
and increased permeability of the endothelium (Gautam et al., 2001). Azurocidin 
deposited on endothelium enhances monocyte arrest (Soehnlein et al., 2005) and 
contributes to the up-regulation of adhesion molecules (ICAM-1, VCAM-1 and E-
selectin) on endothelial cells, which promotes interactions of the endothelium with 
neutrophils and monocytes (Lee et al., 2003). Endothelium-bound azurocidin is 
internalized and protects endothelial cells from apoptosis (Olofsson et al., 1999). The 
exact mechanisms of azurocidin signalling is not determined (Linder et al., 2010), 
however, azurocidin has been shown to activate protein kinase C in endothelial cells 
(Pereira et al., 1996).  
Binding of azurocidin to the protease inhibitor aprotinin inhibits permeability 
changes induced by azurocidin (Gautam et al., 2001; Petersen et al., 1993). 
 
1.4.2.3 Chemotactic activity 
Azurocidin was first shown to have chemotactic effects on monocytes and 
fibroblasts (Flodgaard et al., 1991b). It is also a chemoattractant of T lymphocytes, 
neutrophils and microglia, the mononuclear phagocytic cell of the central nervous 
system (Chertov et al., 1996; Chertov et al., 1997; Pereira et al., 2003). Secreted 
azurocidin can bind to monocytes, which results in internalization of azurocidin 
(Heinzelmann et al., 1999; Heinzelmann et al., 1998). This has shown to prolong 
monocyte survival and to potentiate LPS-induced production of proinflammatory 
cytokines e.g. tumor necrosis factor-alpha (TNF-α) and IL-6 production from 
monocytes (Heinzelmann et al., 1999; Ostergaard and Flodgaard, 1992). 
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1.4.2.4 Expression in chronic inflammation and in non-PMN cells 
Azurocidin is an important neutrophil-derived inflammatory mediator in acute 
inflammation. In addition, azurocidin has been detected in chronic inflammation and 
can be induced by proinflammatory cytokines and LPS in other types of cells. 
Azurocidin has been identified in endothelial cells (Lee et al., 2002) and smooth muscle 
cells (SMC) (Gonzalez et al., 2004; Pereira et al., 1996) of atherosclerotic plaques, and 
in endothelial cells in cerebral microvasculature in Alzheimer's disease. Expression of 
azurocidin in normal endothelium and SMC was not detected, but was induced in 
endothelial cells in response to TNF-α, IL-1α and LPS (Lee et al., 2002; Pereira et al., 
1996) and in smooth muscle cells in response to platelet-derived growth factor (PDGF) 
(Gonzalez et al., 2004).  
The expression of azurocidin in SMC in atherosclerotic plaques was mainly 
observed in proliferating cells. Besides, azurocidin was found to stimulate proliferation 
and migration in vitro in aorta smooth muscle cells and to increase the levels of ICAM-
1 (Gonzalez et al., 2004). 
Pereira et al. studied the effect of azurocidin on corneal wound healing and found 
that azurocidin stimulated proliferation, migration and that adhesion molecules (ICAM-
1, PECAM-1) and integrin molecules (α3, β1) were up-regulated in human corneal 
epithelial cells (Pereira et al., 2004). The expression of azurocidin was inducible in 
corneal epithelium by TNF-α and IL-1β (Ruan et al., 2002). This indicates that 
azurocidin is involved in diseases involving inflammation. 
A recent study has shown that monocytes stimulated with LPS can secrete 
azurocidin (Schou et al., 2011). 
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2 AIMS  
 
1. To further characterize a specific IGFBP-1 protease activity purified from a 
patient’s urine, and to explore whether IGFBP-1 protease activity and IGFBP-1 
fragments were presents in serum of the patient. 
 
2. To determine expression of azurocidin and components of the IGF-system in 
human mast cells. 
 
3. To determine any proteolytic effects of neutrophil-derived azurocidin on the six 
different IGFBPs, focusing especially on IGFBP-1.  
 
4. To determine glycosylation and size of proteolytically active neutrophil-derived 
azurocidin. 
 
5. To study biological functions of the IGFBP-1 and IGFBP-2 fragments on cell 
migration and on IGF-stimulated cell proliferation of primary human dermal 
fibroblasts. 
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3 METHODOLOGY 
 
3.1 MATERIALS  
All peptides used were the human isoforms. Recombinant full-length non-
phosphorylated IGFBP-1 and phosphorylated IGFBP-1 were gifts from Kabi 
Pharmacia (Sweden). Highly phosphorylated HepG2-purified IGFBP-1 and a 
dephosphorylated preparation from the same source were purchased from Sigma–
Aldrich (Sweden). Recombinant npIGFBP-1 and pIGFBP-1 were iodinated by the 
chloramine T method and purified on a PD-10 G25 column (Amersham Biosciences, 
UK). Recombinant pIGFBP-1 was biotinylated at the N-terminus with sulfo-NHS-LC-
LC-biotin (EZ-Link, Pierce, IL, USA) according to the product instructions.  
Human neutrophil-derived azurocidin and a rabbit polyclonal antibody against 
human neutrophil-derived azurocidin were purchased from Athens Research and 
Technology (Athens, Georgia, USA).  Recombinant IGF-I (used in paper I) was a gift 
from Kabi Pharmacia (Sweden). IGF-II was donated by Eli Lilly (Indianapolis, IN). 
The recombinant proteins; glycosylated IGFBP-3, glycosylated IGFBP-4, glycosylated 
IGFBP-5, IGFBP-6, IGF-I (used in paper III) , biotinylated IGF-I and biotinylated 
IGF-II and native IGFBP-1 purified from amniotic fluid, were from GroPep Limited 
(Adelaide, Australia). Recombinant IGFBP-2 was from Sandoz (Basel, Switzerland) 
and kindly provided by Christine Carlsson-Skwirut. 
In paper I, two polyclonal rabbit anti-human IGFBP-1 antibodies were used, both 
of which had been raised against pIGFBP-1. One, KH103, was raised in-house (Povoa 
et al., 1984b) and the other, SU12, by Medprobe (Norway). Monoclonal antibodies to 
human IGFBP-1, mab6303 and mab6305, were gifts from Riitta Koistinen (Helsinki 
University Central Hospital, Finland) and were provided in a concentration of 1 µg/ml. 
In paper III, the mouse monoclonal anti-human integrin α5β1 antibody was from 
Abcam (Cambridge, UK). 
 
3.2 CLINICAL SAMPLES  
Urine and serum samples were obtained from a patient, a 73-year old woman with 
multiple myeloma and a long history of atopy with inflammatory skin lesions and 
eosinophilia (Wang et al., 2006b). Serum creatinine and cystatin C concentrations were 
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within the normal range for her age. Control serum was pooled from 6 healthy 
postmenopausal women. The study was approved by the local Ethics Committee. 
 
3.3 PURIFICATION OF PROTEASE ACTIVITY FROM URINE  
The IGFBP-1 protease was purified by heparin-affinity chromatography as 
previously described (Wang et al., 2006b). In brief, urine from the patient was diluted 
1:5 in 10 mM sodium phosphate, with 0.25 M NaCl, pH 7, and incubated in batches 
with heparin-agarose gel (Amersham Biosciences) for 30 min with continuous stirring. 
After washing the gel with 10 volumes of loading buffer, the salt content was increased 
to 2 M NaCl. The eluate was desalted (to 0.2 M NaCl), concentrated using a 10 kDa 
cut-off MicrosepTM spin column (PALL Life Sciences, USA), and stored at - 80˚C. 
 
3.4 PROTEIN ANALYSIS  
Protein identification and N-Glycosylation site analysis of the neutrophil-derived 
azurocidin preparation was performed by MALDI-TOF peptide mass fingerprint and 
MALDI-TOF/TOF peptide sequencing by Alphalyse A/S (Odense, Denmark). To 
determine N-linked glycosylation sites a sample of azurocidin was incubated with 
PNGase F to remove N-glycans before sequencing and compared to non-treated 
azurocidin. The preparation was also analysed by Hans Jörnvall´s laboratory using 
HPLC-separation, followed by Edman degradation. 
 
3.5 PROTEOLYSIS OF PROTEINS  
Proteolysis of IGFBPs was carried out by incubation with azurocidin in phosphate-
buffered saline (PBS) pH 7.0 for 2 h at 37 °C in a final volume of 10 μL. In Paper II, 
incubation of IGFBP-1 bound to IGF-I or IGF-II was performed in the same manner 
after cross-linking, using disuccinimidyl suberate (DSS) (Pierce, Rockford, IL) 
according to the manufacturer's instructions. The effect of IGFs on the proteolysis of 
IGFBP-1 was determined by incubating biotinylated IGFBP-1 with IGF-I or IGF-II for 
2 h before adding azurocidin. These samples were not cross-linked. Thirteen nM of 
biotinylated IGF-I or IGF-II was incubated with increasing concentrations of 
azurocidin, elastase, cathepsin G or proteinase 3 in PBS in a final volume of 10 µl for 2 
h at 37 °C. 
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The effect of IGFBP-1 fragments and IGFBP-2 fragments on migration and 
proliferation were studied in paper III. These fragments were obtained by incubating 
IGFBP (20 ng/µl) with azurocidin at a 1:1 molar ratio of IGFBP to azurocidin in PBS 
pH 7.0 for 2 hours at 37˚ C in a final volume of 90 µl.  
 
3.6 SDS-PAGE  
Samples were separated on SDS-PAGE under non-reduced or reduced conditions 
after proteolysis. Biotinylated proteins were visualized using neutravidin-horseradish 
peroxidase (Pierce) and detected by ECL (Amersham Biosciences, Uppsala, Sweden). 
S35-labeled proteins were visualized by autoradiography. Non-biotinylated IGFBPs and 
azurocidin were separated on SDS-PAGE and detected by silver staining using the 
SilverQuest kit (Invitrogen, Stockholm, Sweden). Densitometric analysis of stained 
bands was conducted using the software NIH ImageJ (http://rsb.info.nih.gov/ij/). 
 
3.7 IN VITRO TRANSCRIPTION/TRANSLATION OF IGFBP-1 
FRAGMENTS  
In vitro-translated proteins corresponding to the IGFBP-1 fragments generated by 
specific protease activity were produced in order to study their size and 
immunoreactivity, compared to intact IGFBP-1. Total RNA isolated from HepG2 cells 
was reverse-transcribed and first-strand cDNAs were used for PCR. Oligonucleotide 
primers for PCR of N-terminal recIGFBP-11–130 fragment: forward primer 50-
TTCTCGAGATGTCAGAGGTCCCCGTTGCT-30 and reverse primer 50-
TTTCTAGAT TAGATGGCGTCCCAAAGGATGGA-30 and of C-terminal 
recIGFBP-1131–234 fragment: forward primer 50-
TTCTCGAGATGAGTACCTATGATGGCTCGAAG-30 and reverse primer 
50-CCTCTAGACATCTGGTTTCAGTTTTGTACATTAAA-30. The forward primers 
contain a restriction site for XhoI and reverse primers a restriction site for XbaI. The 
PCR cycles for the N-terminal fragment were as follows: 94 °C for 3 min followed by 
35 cycles of 94 °C for 30 s, 60 °C for 30 s, 72 °C for 30 s, and finally 72 °C for 10 min. 
The PCR cycles for the C-terminal fragment were as follows: 94 °C for 3 min followed 
by 35 cycles of 94 °C for 30 s, 65 °C for 30 s, 72 °C for 30 s, and finally 72 °C for 10 
min. The N-terminal (483 bp) and the C-terminal fragment (334 bp) PCR products 
were gel-purified and TA cloned according to the manufacturer’s instructions 
(Invitrogen, Sweden). Plasmid DNA was purified (E.Z.N.A Plasmid Mini Kit I, 
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Omega) and sequenced using Big Dye Terminator Kit and an automatic sequencer 
(both from Genetic Analyzer 3100, Applied Biosystems). Plasmids containing the 
correct inserts were subsequently cleaved with XhoI and XbaI and cloned into the 
pTNT vector (Promega) according to the product instructions. Plasmid 
DNA was purified, sequenced and used for in vitro transcription/translation using the 
TNT Quick Coupled Transcription/Translation Systems (Promega) with incorporation 
of 35S-labeled methionine. Samples of labeled products were separated by 12% SDS–
PAGE, subjected to autoradiography and analyzed on a PhosphorImager scanner (Fuji 
film Bas-2500). The immunoreactivity of the in vitro translated products was analyzed 
by RIA as described below. 
 
3.8 SIZE-SEPARATION COLUMN CHROMATOGRAPHY  
IGFBP-1 fragments were size-separated under non-denaturing conditions. Samples 
containing 125I-pIGFBP-1 (180,000 cpm with 22 µl serum), in a final volume of 400 µl 
in column buffer (0.05 M PBS, pH 7) or cleaved biotinylated pIGFBP-1 in 400 µl 
column buffer were applied to a Superose 12 HR 10/30 column (Amersham 
Biosciences) equilibrated with column buffer. The flow rate was 400 µl/min, and 1 min 
fractions were collected. The column was calibrated with standards from Amersham 
Biosciences (BSA, chymotrypsinogen and ribonuclease A) and recIGF-I (a gift from 
Kabi Pharmacia Sweden, to K.H.). Samples containing IGFBP-1 and its fragments 
were analyzed by gamma counting, chemiluminescence after SDS–PAGE or 
radioimmunoassay, as appropriate.  
 
3.9 RADIOIMMUNOASSAYS  
Four radioimmunoassays were used; an in-house RIA using a polyclonal antibody 
raised against pIGFBP-1 (KH103), previously described (Povoa et al., 1984b), and 
three new RIAs, using the polyclonal antibody SU12 (1:36 000/1:18 000) and two 
monoclonal antibodies, 6303 (1:720 000) and 6305 (1:720 000). In each assay 
recombinant npIGFBP-1 was iodinated and used as tracer (8000 cpm/assay tube). 
Samples were incubated with antibody and tracer in Tris assay buffer, 1% bovine 
serum albumin, in a final volume of 300 µl. After overnight incubation at 4 °C, bound 
counts were separated with goat anti-rabbit, or goat anti-mouse antibody as appropriate 
(SacCel, Boldon, England). 
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3.10 LIGAND-BINDING ASSAYS  
Ligand-binding was performed by incubating biotinylated IGFBP-1 with an excess 
of IGF-I or IGF-II in PBS pH 7.0 at 22 °C for 2 h followed by cross-linking, using a 
final concentration of 0.25 mM DSS. The samples were divided equally into four 
Eppendorf tubes and proteolysis was carried out by incubating with 0, 1, 10 or 100 ng 
of azurocidin in a final volume of 10 μL. 
 
3.11 CELL CULTURE  
Primary human dermal fibroblasts from two donors (HDF) (Promocell, Germany) 
were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 
10% heat-inactivated fetal bovine serum (Invitrogen, Sweden), 2 mM L-glutamine, 100 
IU/ml penicillin and streptomycin at 37°C in 5% CO2 humidified environment. Cell 
studies were performed between passage numbers 4 and 7. Human mast cells (HMC-1) 
(kindly provided by J.H Butterfield at the Mayo Clinic) cells were maintained in 
Iscove´s modified Dulbecco´s medium (IMDM) supplemented with 1 .2 mM alpha 
thioglycerol and 10% FBS. 
 
3.12 THYMIDINE INCORPORATION  
Proliferation of fibroblasts was determined by quantifying DNA synthesis through 
the incorporation of [3H] thymidine. Fibroblasts were plated in 24-well plates and 
experiments were carried out at approximately 30% or 60% confluence. Cells were 
incubated in serum-free medium for 24 h before adding the different media conditions 
for a further 22 h, with [3H] thymidine (1 μCi/ml) added for the last 4 h. The medium 
was removed and cells were rinsed twice with 1 mL ice-cold 0.09% NaCl and then 
incubated with 1 mL ice-cold 5% trichloroacetic acid (TCA) for 15 min. The fixed 
nucleotides were solubilized in 0.5 mL of 0.1 M NaOH for 2 h at room temperature 
under constant shaking. The radioactivity was measured in a β-counter after the 
addition of Ultima Gold scintillation liquid to the samples.  
 
3.13 IN VITRO MIGRATION ASSAY  
Cell migration of fibroblasts was studied using the in vitro “scratch” assay earlier 
described by Li et al. 2004 (Li et al., 2004). Twelve-well plates were pre-coated with 
collagen (50 µg/ml) and blocked with 3% BSA. A sufficient number of cells were 
plated to reach confluence right after attachment of cells. Cells were starved over-night 
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and scratches were made the following day by using a micropipette tip. Floating cells 
were removed by washing with PBS before media containing 0.2% FBS and different 
experimental conditions were added.  Mitomycin C (10 µl/ml) was included in the 
media to prevent cell proliferation. Scratches were photographed with an inverted phase 
microscope before and after the 7 h treatment and migration was calculated from the 
cell-free area after treatment relative to before treatment, using software NIH ImageJ 
(http://rsb.info.nih.gov/ij/). To examine the involvement of the RGD-sequence on 
migration, cells were pre-incubated with a monoclonal α5β1 integrin antibody (diluted 
1:1000) 30 minutes prior to treatment. 
 
3.14 STATISTIC ANALYSES 
Statistical analyses were performed using GraphPad Prism version 5.04, GraphPad 
Software (San Diego, CA, USA). The values are the mean ± SEM. All statistical tests 
were performed with one-way ANOVA or unpaired Student t-test and followed by 
Bonferroni post-test or Dunnett’s Multiple Comparison Test when appropriate. Results 
with a P-value of < 0.05 were considered statistically significant. Significance is 
denoted as *<0.05, **<0.01 and ***<0.001. 
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4 RESULTS AND DISCUSSION  
 
4.1 CHARACTERIZATION OF IGFBP-1 PROTEOLYSIS IN A PATIENT 
(PAPER I) 
Our group has previously purified an IGFBP-1 specific protease activity from the 
urine of a 73 year old patient with multiple myeloma and an inflammatory skin disease 
(Wang et al., 2006b). This activity cleaved both phosphorylated and non-
phosphorylated IGFBP-1 efficiently at a unique site (Ile130–Ser131).  The protease 
activity was identified as azurocidin, based on the presence of azurocidin in partially 
purified material from urine and the inhibitory effect of an antibody to azurocidin. 
However, the protease activity of azurocidin was not isolated in its active form and it 
was destroyed by reverse phase HPLC (Wang et al., 2006b).  
Since azurocidin previously has been reported to be proteolytically inactive 
(Campanelli et al., 1990b; Pereira et al., 1990b; Wilde et al., 1990b), the activity of the 
patient-derived azurocidin was speculated to be unique. 
 
4.1.1 Size-analysis of IGFBP-1 fragments 
IGFBP-1 fragments generated by the partially purified material of azurocidin 
(ppm) were previously purified on HPLC and peaks were sequenced and visualized on 
SDS-PAGE (Wang et al., 2006b). Two main fragments were detected. The N-terminal 
fragment (IGFBP-11-130) migrated at approximately 20 kDa which is higher than its 
predicted molecular mass. The predicted molecular mass of the N-terminal fragment 
(IGFBP-11–130) was 13.4 kDa on MALDI-MS; while a C-terminal fragment (IGFBP-
1142–234) had a mass of 10.8 kDa on MALDI-MS. The predicted molecular masses of 
the specific IGFBP-1 fragments, based on amino acid compositions, are 13.4 and 10.9 
kDa, for IGFBP-11–130 and IGFBP-1142–234 respectively. The observed masses (on SDS–
PAGE and mass spectrometry) and theoretical masses of the N- and C-terminal IGFBP-
1 fragments are shown in Table 3. 
 
 
 
 
 
 
   25 
Table 3. Comparison of observed and theoretical masses of intact, N- and C-terminal  
fragments of IGFBP-1. 
     SDS-PAGE Mass spectrometry Theoretical mass 
Intact pIGFBP-1 28–30 kDa  25.2 kDa  25.3 kDa 
N-terminal fragment 
   In vitro (N-IGFBP-11–130)a 21.5 kDa  N.D.  13.4 kDa 
Purified (IGFBP-11–130) 20 kDab   13.4 kDa 13.4 kDa 
C-terminal fragment 
   In vitro (C-IGFBP-1131-234)a 11.4 kDa  N.D.  11.9 kDa 
Purified (IGFBP-1142–234) 14 kDab   10.8 kDa 10.9 kDa 
Molecular masses of intact and cleaved IGFBP-1 were determined by SDS–PAGE and mass 
spectrometry. The theoretical masses were predicted from the amino acid composition. 
N.D., not determined. 
   a Translated in vitro. 
   b Fragments were purified by HPLC by Wang, Shafqat et al. 
 
 
 Biotinylated pIGFBP-1 was cleaved with the IGFBP-1 protease preparation and 
then size-separated by FPLC under neutral conditions. The presence of biotin (intact 
IGFBP-1 and any fragments containing the N-terminus) was then detected after SDS–
PAGE. When analyzed by RIA, using antibody SU12, the elution profile was complex 
and appeared to represent several immunoreactive peaks over a broad range of 
molecular masses, with most immunoreactive fragments eluting around 13 kDa. 
In order to study the discrepancy in the molecular size of the IGFBP-1 fragments, 
in vitro translated forms were produced and analyzed on SDS–PAGE. The N-terminal 
fragment (IGFBP-11–130) migrated at an apparent molecular mass of 21.5 kDa under 
reducing conditions, which is a similar molecular mass to that generated by cleavage of 
N-terminally biotinylated IGFBP-1 (Wang et al., 2006b).  The C-terminal IGFBP-1131–
234 had an observed molecular mass of 11.4 kDa, close to its theoretical mass of 11.9 
kDa. IGFBP fragments may run anomalously on SDS–PAGE. An N-terminal fragment 
of IGFBP-3 has been observed to migrate at a molecular mass higher than its actual 
size (Salahifar et al., 2000). 
 
4.1.2 Immunoreactivity of IGFBP-1 fragments 
Specific cleavage had little effect on total IGFBP-1 immunoreactivity in three of 
the RIAs. However in one RIA, using monoclonal antibody mab6305, there was a clear 
loss of immunoreactivity. Surprisingly in this assay the recombinant C-terminal 
fragment effectively displaced IGFBP-1 tracer. Since the C-terminal fragment can 
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undergo further proteolysis in the presence of azurocidin (Wang et al., 2006b), this may 
explain the loss of immunoreactivity in an assay that is directed to the C-terminus. 
Indeed C-terminal fragments of approximately 7 kDa were evident after cleavage of 
radiodinated IGFBP-1. 
 
4.1.3 Detection of proteolytic activity and fragments in serum  
We found that the IGFBP-1-specific protease activity was completely abolished in 
the presence of serum from the patient. This is not surprising since a number of 
protease inhibitors are present in the circulation. It has been reported that alpha2-
macroglobulin binds to IGFBP-1 and inhibits the effect of MMP-3 on IGFBP-1 
cleavage (Westwood et al., 2001). Wang et al. have previously shown that this IGFBP-
1-specific protease activity was inhibited by serine protease inhibitors (Wang et al., 
2006b). IGFBP-3 proteases have been reported to be inhibited by serum inhibitors 
(Maile et al., 2000) and it has been proposed that specific degradation of IGFBP-3 
(Koistinen et al., 2002) and IGFBP-4 (Bayes-Genis et al., 2001) occur at the tissue level 
to increase local IGF action. Azurocidin is mobilized from neutrophil secretory 
granules in response to inflammation (Watorek, 2003). It is also expressed in activated 
endothelial cells associated with atherosclerotic plaques (Lee et al., 2002) and with 
Alzheimer’s lesions (Pereira et al., 1996). Co-localization of azurocidin and IGFBP-1 
in these or other sites may regulate IGFBP-1 activity locally. Since no IGFBP-1 
protease activity was detected in the patient serum, activity of this protease is therefore 
likely to have a tissue-specific role. The protease could reach the tissues in an endocrine 
fashion, or may be produced locally; and IGFBP-1 fragments generated in tissues may 
enter the circulation.  
The IGFBP-1-specific protease activity was purified from urine; therefore kidney 
could be a potential source. However, the patient was diagnosed with two inflammatory 
diseases, multiple myeloma and dermatitis, and the activity was co-purified with two 
other neutrophil proteins (Wang et al., 2006b), which suggests that it was derived from 
neutrophils.  
Although there was no circulating protease activity in serum we have evidence that 
immunoreactive fragments of IGFBP-1 are present in the circulation of our patient. 
Circulating IGFBP fragments have previously been reported, however, their presence is 
usually associated with renal failure (Kiepe et al., 2001) and our patient had normal 
renal function.  
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In summary, specific cleavage of IGFBP-1 probably occurs at the tissue level and 
not in the circulation in a patient with multiple myeloma and dermatitis. The fragments 
that are generated may have endocrine roles. 
 
4.2 PROTEOLYTIC EFFECTS OF NEUTROPHIL-DERIVED AZUROCIDIN 
(PAPER II AND III) 
 
4.2.1 Neutrophil-derived azurocidin cleaves IGFBP-1,-2 and -4 (paper II) 
We found that a commercially available preparation of neutrophil-derived 
azurocidin cleaved recombinant phosphorylated IGFBP-1 into three fragments of 22, 
20 and 14 kDa. The fragments were of equal sizes as obtained when phosphorylated 
IGFBP-1 was cleaved with urine-derived (from patient) azurocidin (Wang et al., 
2006b). See section 4.5.1 for a comparison between urine-derived and neutrophil-
derived azurocidin.  
The effect of neutrophil-derived azurocidin on native IGFBP-1 purified from 
amniotic fluid was also studied and detected by silver staining. Native IGFBP-1, which 
consists of three to four phosphorylated forms of IGFBP-1, was cleaved into three 
fragments of 23, 20 and 14 kDa. The proteolytic effect was detected at picomolar 
concentrations of azurocidin which is considerably less than required for other effects 
of azurocidin. Antimicrobial and chemotactic effects are exerted by azurocidin at µM 
concentrations. The proteolytic effect of neutrophil-derived azurocidin was inhibited by 
a polyclonal antibody against azurocidin (see section 4.5.1).   
Neutrophil-derived azurocidin also cleaved IGFBP-2 and IGFBP-4. Incubation of 
IGFBP-2 with azurocidin resulted in two fragments of approximately 23 and 19 kDa, 
while glycosylated IGFBP-4 of 24–28 kDa was cleaved into one major fragment of 
approximately 17 kDa and one minor fragment of approximately 15 kDa. Azurocidin 
was previously reported to be an IGFBP-1 specific protease (Wang et al., 2006b). The 
contradictive results could be due to different methods of detection. In the former report 
radioiodinated IGF-I was used to visualize IGFBPs and possible fragments, while we 
used silver staining. It has been shown that IGFBP-4 fragments produced by the 
protease PAPP-A have markedly reduced affinity for IGFs compared to intact IGFBP-4 
(Boldt and Conover, 2007). Proteolytic fragments of IGFBP-2 have also been shown to 
have decreased affinity for IGFs compared with intact protein (Firth and Baxter, 
2002a).  In paper III, we show that proteolysis of phosphorylated IGFBP-1 did not 
 28 
alter its inhibitory effects on IGF-induced proliferation, which could be due to efficient 
binding between IGFBP-1 fragments and IGFs. 
 
4.2.2  Effects of IGFs on IGFBP-1 proteolysis (paper II)  
Phosphorylated IGFBP-1 has higher affinity for IGFs compared to less 
phosphorylated IGFBP-1 and has been reported to be resistant to proteolysis (Gibson et 
al., 2001). To determine the effect of the neutrophil-derived azurocidin preparation on 
IGF-bound phosphorylated IGFBP-1, IGFBP-1 was ligand-bound and cross-linked to 
IGF-I or IGF-II before being incubated with the azurocidin-preparation. We observed 
cleavage of phosphorylated IGFBP-1 when bound to IGF-I. Increasing concentrations 
of azurocidin reduced IGF-I / IGFBP-1complexes and intact IGFBP-1, while the 22-
kDa fragments increased. The amount of cleavage of IGF-I-bound IGFBP-1 was not 
possible to determine since both unbound and ligand-bound IGFBP-1 coexisted in the 
reaction tube and fragments might descend from both forms of IGFBP-1. However, the 
highest concentration of azurocidin resulted in almost complete loss of ligand-bound 
IGFBP-1, which supports proteolysis of IGF-I-bound IGFBP-1. It is uncertain if IGF-
II-bound IGFBP-1 was cleaved or not. This complex appears faint compared to IGF-I-
bound IGFBP-1, which might be due to less efficient ligand-binding. However, in the 
presence of IGF-II and in comparison to IGF-I, proteolysis of IGFBP-1 was 
significantly reduced. This method is not reliable to quantify and compare proteolysis 
of unbound and IGF-bound IGFBP-1 as the presence of DSS and an excess of IGFs 
could also have an impact on the proteolysis of IGFBP-1. The biotin molecule attached 
to IGFBP-1 could also be less visible on the blot when bound to IGFs due to 
conformational changes.  
Since proteolysis of IGFBP-1 was reduced in reactions containing IGF-II, we 
studied the effect of IGF-I and IGF-II on IGFBP-1 proteolysis.  The effect of IGFs on 
the proteolysis of IGFBP-1 was determined by pre-incubating IGF-I or IGF-II with 
IGFBP-1 for 2 h, but without cross-linking proteins, before incubating with azurocidin. 
IGF-II showed inhibitory effect on IGFBP-1 proteolysis, while IGF-I had no effect on 
cleavage of IGFBP-1. Proteolysis in the absence of IGFs resulted in 80% cleavage of 
intact IGFBP-1. At a 1:1 ratio of IGFBP-1 to IGF-II, cleavage of intact IGFBP-1 was 
reduced by approximately 50% compared to proteolysis of intact IGFBP-1 in the 
absence of IGF-II.  
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4.2.3 Effects of neutrophil-derived azurocidin on IGFs (paper III) 
The proteolytic activity of neutrophil-derived azurocidin towards IGF-I and IGF-II 
was examined to exclude degradation of these proteins, using the same concentrations 
of azurocidin which efficiently cleaved IGFBP-1, -2 and -4 in paper II.  We have also 
compared the effect of azurocidin to three closely structurally related neutrophil 
proteases; elastase, proteinase 3 and cathepsin G (Figure 2).  Elastase and Cathepsin G 
have earlier been reported to efficiently cleave all six IGFBPs and have been speculated 
to be involved in the regulation of IGFs and IGFBPs during inflammation and wound 
healing (Gibson and Cohen, 1999). Azurocidin had no proteolytic effect on IGF- I or 
IGF-II with the used concentrations. In contrast to azurocidin, we observed cleavage of 
IGF-I and IGF-II by elastase and proteinase 3. Cathepsin G showed proteolytic activity 
towards IGF-I, but not IGF-II.  
In summary, the neutrophil-derived preparation of azurocidin cleaved IGFBP-1, 
IGFBP-2 and IGFBP-4. Phosphorylated IGFBP-1 bound to IGF-I was also degraded 
whereas IGF-II was shown to have an inhibitory effect on proteolysis of 
phosphorylated IGFBP-1. The proteolytically active preparation of neutrophil-derived 
azurocidin was found to be glycosylated and determined to be 31 kDa by SDS-PAGE.  
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4.3 ANALYSIS OF NEUTROPHIL-DERIVED AZUROCIDIN 
This commercially available preparation of azurocidin was purified from 
neutrophils by affinity chromatography and activity assays had been performed for 
proteinase 3, elastase and cathepsin G by Athen’s Research and Technology to rule out 
contamination of these. In paper II we confirmed the identity of the preparation by 
protein sequencing and performed N-Glycosylation site analysis by MALDI-TOF 
peptide mass finger print and MALDI-TOF/TOF peptide sequencing.  
The preparation of neutrophil-derived azurocidin was further analysed by HPLC 
and Edman degradation (not included in papers). Intact azurocidin was found to be the 
main component (approximately 75%). Two fragments of azurocidin were also 
detected in the preparation, one starting from amino acid 41 and the other from amino 
acid 106, which could be the result of autocatalytic activity. A fourth component was 
found and has not been described in the literature earlier.  
Elastase was not detected with these methods and could therefore only be present 
in low concentrations. In addition, elastase (0.3 nM) cleaved both IGF-I and IGF-II, 
while the highest concentration of the azurocidin-preparation (300 nM) showed no 
effects on IGF-I and IGF-II, therefore any contamination of elastase must be less than 
0.1% of the preparation of azurocidin.  
Azurocidin contains three N-linked glycosylation sites that are located at 
asparagine residues 100, 114 and 145.  Different molecular masses have been reported 
(29–37 kDa), which is probably due to different degrees of glycosylation (Watorek, 
2003). Neutrophil-derived azurocidin was glycosylated at asparagine 145 and 
determined to be 31 kDa by SDS-PAGE (paper II). 
 
4.4 BIOLOGICAL EFFECTS OF IGFBP-1 AND IGFBP-2 FRAGMENTS 
(PAPER III)  
The IGF-system  is important in wound healing (Skottner et al., 1988) and our 
results indicate that the inflammatory mediator azurocidin can cleave IGFBP-1, 
IGFBP-2 and IGFBP-4. The C-terminal of IGFBP-1 and IGFBP-2 contain an Arg-Gly-
Asp (RGD) sequence which can bind to cell-surface α5β1-integrins (Brewer et al., 
1988; Jones et al., 1993c). IGFBP-1 has been shown to increase migration 
independently of IGF-I by activating α5β1-integrins (Gleeson et al., 2001; Jones et al., 
1993c; Perks et al., 1999), while there are only a few reports of such IGFBP-2 effects 
(Wheatcroft and Kearney, 2009).  In contrast to IGFBP-4, IGFBP-1 and IGFBP-2 are 
   31 
cleaved into stable fragments by the neutrophil-derived preparation of azurocidin and 
contain a RGD-sequence (paper II). We therefore studied the effect of IGFBP-1, 
IGFBP-2 and their fragments on migration and proliferation, which are important in 
wound healing. Fibroblasts were used as they are involved in the inflammatory process 
and maintain the extracellular matrix (Glaros et al., 2009). To obtain fragments for 
these studies, IGFBP-1 and IGFBP-2 were incubated with the neutrophil-derived 
preparation of azurocidin until (2 h) all intact protein was degraded into fragments 
(Figure 3). 
 
 
 
 
4.4.1 Effects on migration of fibroblasts 
We studied the effect of IGFBP-1, IGFBP-2 and their fragments on migration of 
human dermal fibroblasts for 7h by using the in vitro “scratch” assay earlier described 
by Li et al. 2004 (Li et al., 2004). IGFBP-1 fragments and IGFBP-2 fragments 
stimulated migration of fibroblasts as efficiently as intact IGFBP-1 and IGFBP-2. 
IGFBP-1 and IGFBP-1 fragments stimulated migration of fibroblasts by around 40%, 
while IGFBP-2 and its fragments increased migration by approximately 50% compared 
to controls. The effect of azurocidin was also determined as the preparations of 
fragments contained azurocidin, but no effect was detected. These results support 
another study by Sala et al., which demonstrated that a C-terminal fragment isolated 
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from amniotic fluid retains the capability of intact IGFBP-1 to stimulate cell migration 
(Sala et al., 2005).  
To determine whether the increased migration involved binding of IGFBP C-
terminal RGD-sequence to α5β1 integrin, cells were pre-incubated with a monoclonal 
α5β1 integrin antibody prior to the treatment with intact IGFBPs or fragments. The 
antibody abolished the stimulatory effect of IGFBP-1, IGFBP-2 and fragments on 
migration, which suggests that the increased migration involves an interaction of the 
RGD-sequence with α5β1 integrins. IGFBP-1 stimulated migration has earlier been 
shown to be blocked by pre-incubating with an anti-α5β1 antibody (Gleeson et al., 
2001). 
 
4.4.2 High glucose decrease migration of fibroblasts 
High glucose (25 mM) decreased migration of fibroblasts by approximately 45% 
compared to migration in normal glucose. This supports an earlier study where high 
glucose levels (25 mM) reduced migration of cardiac fibroblasts (Zhang et al., 2007). 
The addition of IGFBP-1, IGFBP-2, IGFBP-1 fragments or IGFBP-2 fragments 
increased migration in high glucose to normal levels, equivalent to migration in normal 
glucose.  
 
4.4.3 Effects on IGF-I stimulated proliferation 
The effect of IGFBP-1 on IGF-I stimulated proliferation of human dermal 
fibroblasts appeared complex. We have observed two different outcomes depending on 
how confluent the cells were at the time of treatment. IGFBP-1 had no inhibitory effect 
on IGF-I stimulation when cells were sparsely plated and approximately 30% at the 
time of experiment. Instead IGFBP-1 potentiated IGF-I activity. IGFBP-1 had no 
potentiating effects on IGF-II (not shown), which suggests that this might be a selective 
effect of IGF-I. These results are supported by two other studies where IGFBP-1 
potentiated IGF-I stimulated proliferation of fetal and adult human fibroblasts, 
respectively (Koistinen et al., 1990; Kratz et al., 1992).   
In experiments when cells were sparsely plated, we also observed increased 
proliferation by the addition of IGFBP-1 or azurocidin alone. Azurocidin and IGFBP-1 
stimulate proliferation more than 2-fold compared to controls. Azurocidin-increased 
proliferation could be due to cleavage of endogenously produced IGFBPs and a 
subsequent increase in bioavailable IGFs or perhaps azurocidin stimulated proliferation 
on its own. Azurocidin has previously been reported to promote proliferation and to up-
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regulate adhesion molecules (ICAM-1, PECAM-1) and integrin molecules (α3, β1) in 
corneal epithelial cells (Pereira et al., 2004). Azurocidin was also found to stimulate 
proliferation and migration and to increase the levels of ICAM-1 in vitro in aorta 
smooth muscle cells (Gonzalez et al., 2004). The exact mechanisms azurocidin 
signalling is not determined (Linder et al., 2010). However, the molecule of azurocidin 
has a strong dipole moment caused by basic amino acids concentrated on one side of 
the molecule and has been shown to bind to (Iversen et al., 1997) negatively charged 
proteoglycans on the endothelial cell membrane (Olofsson et al., 1999). The 
stimulatory effect of IGFBP-1 could be due to potentiation of endogenously produced 
IGF-I or be the result of IGF-independent stimulation by IGFBP-1.   
When cells were more confluent (approximately 60%) at the time of experiment, 
IGFBP-1 inhibited IGF-I stimulated proliferation, and at even higher densities the 
stimulatory effect of IGFs on fibroblasts disappeared (not shown). In these experiments 
neither IGFBP-1 nor azurocidin showed any stimulatory effects on proliferation of 
fibroblasts on their own 
Proteolysis of phosphorylated IGFBP-1 had no effect on potentiating or inhibitory 
effects of IGFBP-1 on IGF-I stimulated proliferation since we observed similar results 
with the proteolytic fragments of IGFBP-1.  
The phosphorylation state of IGFBP-1 has been reported to determine whether 
IGFBP-1 inhibits or potentiates IGF activity: phosphorylated IGFBP-1 increased 
binding affinity and favoured inhibition, while non-phosphorylated IGFBP-1 was 
associated with potentiation of IGF-I activity (Jones et al., 1991). According to our 
results, the state of phosphorylation of IGFBP-1 does not determine if IGFBP-1 inhibits 
or potentiates IGF action since we used phosphorylated IGFBP-1 and obtained both 
inhibitory and potentiating effects. Instead, we observed that the effects of IGFBP-1 on 
IGF activity was depending on cell confluence.  
Human dermal fibroblasts have been reported to secrete IGF-I and IGFBP-3, but 
not IGFBP-1 (Conover et al., 1989). However, in this reported study binding-proteins 
were detected in conditioned medium from confluent cells. Another study has shown 
that human fetal fibroblasts release IGFBP-1, but only when sparsely plated and rapidly 
growing (Hill et al., 1989). Martin and Baxter have shown that secretion of IGFBP-1 
from human neonatal fibroblasts disappeared as concentrations of exogenous IGFBP-3 
increased (Martin and Baxter, 1992). It is therefore uncertain whether human dermal 
fibroblasts secrete IGFBP-1 or not when sparsely plated. The secretion of IGFs and 
IGFBPs from fibroblasts at different confluence and the interactions of these needs to 
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be further studied in order to understand the complexity of the IGF-system in wound 
healing.  
 
4.4.4 Effects on IGF-II stimulated proliferation 
The general function of IGFBP-2 is to inhibit IGF actions, in particular IGF-II, 
since it has higher affinity for IGF-II (Firth and Baxter, 2002b). Our results demonstrate 
that in contrast to IGFBP-1, proteolysis of IGFBP-2 affected the inhibitory effect on 
IGFs. Intact IGFBP-2 inhibited IGF-II induced proliferation while IGFBP-2 fragments 
had no significant inhibitory effects. It is possible that the N- and C-terminals of 
IGFBP-1 bind independently of each other to IGFs, while both ends of IGFBP-2 might 
be required for the same task. The N- and C-terminal domains of IGFBP-2 cooperate in 
IGF binding (Kuang et al., 2007). 
In summary, IGFBP-1 fragments and IGFBP-2 fragments stimulated migration as 
efficiently as intact IGFBP-1 and IGFBP-2. The stimulatory effect was abolished by 
pre-treating cells with a α5β1 integrin antibody. High glucose impaired migration, 
however, the addition of IGFBP-1, IGFBP-2 or fragments increased migration to levels 
observed in normal glycaemia. IGFBP-2 inhibited IGF-II induced proliferation, 
whereas IGFBP-2 fragments had no significant inhibitory effect. The effect of intact 
IGFBP-1 and IGFBP-1 fragments on IGF-I induced proliferation had both potentiating 
and inhibitory effects, depending on the confluence of cells. We also observed 
stimulatory effects of both IGFBP-1 and azurocidin alone on proliferation of 
fibroblasts. The IGFBP-fragments obtained by incubating intact proteins with a 
neutrophil-derived preparation of azurocidin had effects on both migration and 
proliferation of human dermal fibroblasts, implicating effects of azurocidin and IGFBP-
fragments on wound healing (Figure 4). 
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4.5 RESULTS NOT INCLUDED IN PAPER I-III 
 
4.5.1 Analysis of neutrophil-derived azurocidin 
Azurocidin purified from the patient was earlier speculated to be unique as 
azurocidin previously has been reported to be proteolytically inactive. In Figure 5, 
biotinylated recombinant pIGFBP-1 was 
cleaved with either 10 ng of neutrophil-
derived azurocidin or 1 µl of partially 
purified azurocidin from the urine of our 
patient. Neutrophil-derived azurocidin 
cleaved approximately 84% of intact 
IGFBP-1 while urine-derived azurocidin 
degraded around 73%. 
The proteolytic effect of neutrophil-
derived azurocidin was blocked by a 
polyclonal antibody against azurocidin 
(Figure 6). Proteolysis of IGFBP-1 by 
neutrophil-derived elastase was also 
inhibited by this antibody, but only with the 
highest concentration of antibody and not in 
a dose-dependent manner as azurocidin.  
 Azurocidin can bind to LPS and neutralize its endotoxic effects (Brackett et al., 
1997; Pereira et al., 1993). We studied the proteolytic effect of azurocidin when co-
incubated with LPS and found no effect of LPS on proteolysis of IGFBP-1 by 
neutrophil-derived azurocidin 
(not shown). 
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4.5.2 Expression of recombinant azurocidin  
We produced recombinant azurocidin by in vitro transcription/translation in 
reticulocyte lysate. The recombinant azurocidin showed no proteolytic effect on 
biotinylated IGFBP-1, which could be due to the lack of glycosylations. We show in 
paper II that proteolytically active azurocidin was glycosylated at asparagine 145. 
Recombinant non-glycosylated azurocidin has earlier been shown to have lower 
biological activity compared to glycosylated azurocidin, which suggests that 
glycosylation of azurocidin affects its biological activity (Iversen et al., 1999). Since 
transcription/translation was performed in a reticulocyte lysate, which could contain 
protease inhibitors, we examined the effect of the reticulocyte extract on the proteolytic 
activity of urine-derived azurocidin. IGFBP-1 was not cleaved by urine-derived 
azurocidin in the presence of the reticulocyte extract; however, the protease activity 
was regained after purification with heparin affinity chromatography (not shown).  
 
4.5.3 Characterisation of the IGF system in human mast cells  
The protease activity used in paper I was isolated from the urine of a patient who 
suffered from an inflammatory skin disease. Therefore we studied the expression of 
azurocidin and components of the IGF-system in human mast cells. The human mast 
cell line HMC-1 is an immature haematopoietic cell line derived from a patient with 
mast cell leukemia and the only established cell line exhibiting a phenotype similar to 
that of human mast cells (Butterfield et al., 1988). These cells contain tryptase and 
produce heparin. 
The expression of mRNA was determined by RT-PCR and HMC-1 cells were 
found to express IGF-II, IGF-
1R, IGFBP-1, IGFBP-2 and 
azurocidin (Figure 7). Initial 
studies also showed secretion of 
IGFBP-1, but this was not a 
consistent finding and needs to be further studied. IGF-II is often up-regulated in cancer 
and is proposed to be an autocrine regulator in tumor cell growth. In Figure 8 we 
propose a possible model for local regulation of IGFs in human mast cells. 
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When maintained in 10% fetal calf serum these cells grow in suspension culture, 
however, under serum-free conditions the cells adhere to plastic. In preliminary studies 
we found that, in the presence of the specific Type 1 IGF receptor antagonist 
picropodophyllin, the number of cells unattached to the culture plates was 2-fold 
greater than in control wells. This supports a recent study which shows that IGF-I 
promotes mast cell survival via activation of the phosphatidylinositol-3-kinase pathway 
(Lessmann et al., 2006).  
 
4.5.4 Splice variants of azurocidin  
 A role for splicing in regulation of azurocidin actions has not been described 
earlier. Unpublished data obtained in connection with studies regarding mRNA 
expression of azurocidin in mast cells and human leukocytes indicate that this could be 
the case. Three splice variants encoding peptides with the N-terminal of azurocidin 
followed by a short unrelated C-terminal was identified (Figure 9). Two of these 
variants contain residues 20-44 of azurocidin, which has been reported to mimic the 
bacterial action of azurocidin (Pereira et al., 1993). The fact that one of these splice 
products was found in both a mast cells and in leukocytes indicate a possible biological 
relevance. The protein level of azurocidin could be regulated by mRNA splicing and/or 
spliced azurocidin mRNA could be translated and serve some yet unknown function. It 
remains to be seen if these spliced mRNAs are translated into peptides in vivo. 
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5 GENERAL DISCUSSION 
 
We have observed cleavage of IGFBP-1 with the same fragmentation pattern by a 
novel protease-activity obtained from two different sources (urine and neutrophils) 
where azurocidin has been identified as the main component. Both materials have been 
analysed by today’s available methods to exclude the presence of other proteases.  
Although not detected, it is possible that the partially purified material from urine and 
the commercially available neutrophil-derived preparation of azurocidin contain trace 
amounts of other serine proteases. This protease-activity was earlier shown to be 
inhibited by a serine-protease inhibitor (Wang et al., 2006b). It is possible that 
azurocidin needs to be glycosylated to be proteolytically active as the active neutrophil-
derived azurocidin was glycosylated, while the recombinant non-glycosylated 
azurocidin was inactive.  
Regardless of the source of this protease-activity, we have discovered a protease-
activity which specifically cleaves IGFBP-1, -2 and -4 without degrading neither IGF-I 
nor IGF-II. Phylogenetic analyses of IGFBPs have shown that these three binding 
proteins are more closely related to each other than to the other IGFBPs (Rodgers et al., 
2008). These binding-proteins are found in binary complexes with IGFs in the 
circulation and have the ability to leave the vascular compartment, which makes them 
important IGF transporters to target tissues. Besides, in contrast to other IGFBPs, 
IGFBP-1 and IGFBP-2 have both a C-terminal RGD-sequence and are regulated by 
metabolism.  
Since azurocidin is released in inflammation and IGFs are important in wound 
healing, this protease could be an important regulator of IGF-activity in inflammation 
and wound healing. This thesis shows that the proteolytic IGFBP-fragments have 
stimulatory effects on migration and reduced inhibitory effects on IGF-induced 
proliferation compared to intact proteins, and that the addition of azurocidin can 
increase proliferation of human dermal fibroblasts.  
Proteolysis has been described in the literature as the predominant way to release 
IGFs from IGFBPs and to increase bioactive IGFs. The regulation of IGFBP-1 appears 
to be more complex since we found no difference between the regulatory role of 
phosphorylated intact IGFBP-1 and IGFBP-1 proteolytic fragments on IGF-activity. 
Instead cell confluence appeared to regulate the inhibitory and potentiating effects of 
phosphorylated IGFBP-1. 
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These results are of importance for understanding the role of the IGF-system in 
tissue repair and could lead to the development of new treatment strategies. 
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6 CONCLUSIONS 
 
In this thesis we have studied a novel IGFBP protease and the biological effects 
of the proteolytic IGFBP fragments. In summary, the conclusions of this thesis 
are: 
 
1. Although IGFBP-1 fragments were detected in serum, cleavage of IGFBP-1 
probably occurs at the tissue level and not in the circulation in a patient with 
multiple myeloma and dermatitis.  
 
2. A neutrophil-derived preparation of azurocidin cleaves IGFBP-1, IGFBP-2 and 
IGFBP-4 without degrading IGFs. Phosphorylated IGFBP-1, free or bound to 
IGF-I is also cleaved by this preparation, while proteolysis of IGFBP-1 is 
reduced by IGF-II. 
 
3. The proteolytically active preparation of neutrophil-derived azurocidin is 
glycosylated and determined to be 31 kDa by SDS-PAGE. 
 
4. The same cleavage pattern of phosphorylated IGFBP-1 is obtained by 
incubating with either urine-derived (from patient) or neutrophil-derived 
azurocidin preparations. 
 
5. Splice variants of azurocidin are expressed in human mast cells and in human 
leukocytes. The fact that one of these splice products was found in both cell 
types indicate a possible biological relevance. 
 
6. IGFBP-1, IGFBP-2 and their proteolytic fragments stimulate migration of 
human dermal fibroblasts via α5β1-integrins.  
 
 
7. High glucose impairs migration of human dermal fibroblasts and the addition of 
IGFBP-1, IGFBP-2 and their fragments increase migration in high glucose to 
levels observed in normal glycaemia. 
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8. Phosphorylated IGFBP-1 can have both potentiating and inhibitory effects on 
IGF-stimulated proliferation, depending on the confluence of cells. 
 
9. IGFBP-2 fragments have reduced inhibitory effect on IGF-II action compared 
to intact IGFBP-2, while proteolysis of IGFBP-1 does not result in more 
bioactive IGF-I. 
 
10. Neutrophil-derived azurocidin stimulates proliferation of human dermal 
fibroblasts. 
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